HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
Quote:
Login Free Membership
Search:

Analyst Blog  

Conmed Beats Zacks Estimate

Share
By: Zacks Equity Research
May 03, 2010 |Comments: 0
Recommended this article (0)
SYK | SNN | CNMD

Conmed Corporation (CNMD) reported first quarter fiscal 2010 earnings per share of 28 cents, beating the Zacks Consensus Estimate of 26 cents and the year-ago earnings of 19 cents.

Sales
Total revenues in the first quarter increased 7.5% year over year to $176.4 million. Excluding a favorable foreign currency translation, net sales increased 2.7% year over year. Growth was witnessed across all major business segments.
Arthroscopy sales increased 13.0% year over year to $72.2 million. Powered Surgical Instruments sales increased 6.7% year over year to $35.0 million. Electrosurgery sales increased 3.1% year over year to $23.1 million.
Single-use and reposable revenues increased 8.9% year over year to $138.3 million. Capital equipment sales increased 2.7% year over year to $38.1 million.
Margins
Conmed registered an expansion of margins in the first quarter. Gross margin increased 550 basis points (bps) year over year to 52.0%. Selling and administrative expenses as a percentage of sales increased 230 bps year over year to 40.0%. Research and development expenses as a percentage of sales declined 80 bps year over year to 4.4%.
Higher gross margin was primarily responsible for a higher operating margin that increased 320 bps year over year to 7.7%.
Balance Sheet
Conmed ended the first quarter with cash and cash equivalents of roughly $10.0 million, registering a sequential decline of 1.3%. The company had an outstanding debt of approximately $209.1 million at the end of the first quarter.
Outlook
Conmed has maintained its revenues and adjusted earnings per share guidance for fiscal 2010. For the year, the company expects total revenue in the range of $715 million to $725 million. Adjusted earnings per share should be in the range of $1.20 to $1.30.
Conmed has also provided guidance for the next quarter. For the second quarter, total revenue should range between $175 million and $180 million. Adjusted earnings per share should range between 25 and 30 cents.
Conmed is a major medical products manufacturer specializing in surgical instruments and devices. Its main competitors include Stryker Corporation (SYK) and Smith & Nephew (SNN).
Presently, we are ‘Neutral’ on Conmed.

Read the full analyst report on SYK

Read the full analyst report on SNN

Read the full analyst report on CNMD

 
Add a Comment

Please login or register to post a comment



Email

Print

Share

Rate Pos

Rate Neg

Comment
Attn. Zacks.com Visitors
Sell These Stocks Today
Make sure no Zacks #5 Rank "Strong Sell" stocks are lurking in your portfolio. They tend to perform only 1/6th as well as the market!
Get your free Welcome Gifts today*:
 1.  Zacks "Strong Sell" list.
 2.  Our e-newsletter with 4 "Strong Buy" stocks, Bull & Bear of the Day, and market commentary in every issue.
Get them free right now
  
No cost. Unsubscribe anytime. Privacy Policy
*Only for non-members. May end at any time.

More Zacks Resources

Market Summary Feb 03, 2012 21:06 pm ET
DJIA 12862.23  156.82 1.23%
NASD 2905.66  45.98 1.61%
S&P 500 1344.9  19.36 1.46%
Partner Center